No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Rodman & Renshaw Maintains Cassava Sciences(SAVA.US) With Sell Rating, Cuts Target Price to $2
Sector Update: Health Care
Top Midday Decliners
12 Health Care Stocks Moving In Tuesday's Intraday Session
HC Wainwright & Co. Reiterates Neutral on Cassava Sciences, Maintains $2 Price Target
Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop